The Cameco annual report has been published - the link is:
https://s3-us-west-2.amazonaws.com/assets-us-west-2/annual/cameco-2022-information-form.pdf
It has several mentions of GLE (and Silex) the main one is:
"Global Laser Enrichment
GLE is the exclusive licensee of the proprietary Separation of Isotopes by Laser Excitation (SILEX) laser enrichment
technology, a third-generation uranium enrichment technology. We are the commercial lead for the GLE project with a 49%
interest and starting in February 2023, an option to attain a majority interest of up to 75% ownership.
Subject to completion of the technology development program, and its progression through to commercialization, GLE has the
potential to offer a variety of advantages to the global nuclear energy sector over the long-term, which include:•re-enriching depleted uranium tails leftover as a by-product of previous-generation enrichment technologies, repurposing
legacy waste into a commercial source of uranium and conversion products to fuel nuclear reactors and aiding in the
responsible clean-up of enrichment facilities no longer in operation, as per GLE’s agreement with the US Department of
Energy
•producing commercial low-enriched uranium (LEU) fuel for the world’s existing and future fleet of large-scale light-water
reactors with greater efficiency and flexibility than current enrichment technologies
•producing high-assay low-enriched uranium (HALEU), the primary fuel stock for the majority of small modular reactor
(SMR) and advanced reactor designs that are proceeding through the development stage and continuing toward
commercial readiness
In 2022, GLE made progress with the first full-scale laser system module, successfully completing eight months of testing in
Australia, and the system was delivered to GLE’s commercial pilot demonstration facility in the US. In addition, GLE signed
letters of intent to collaborate with two major US utilities to help diversify the US nuclear fuel supply chain, including measures
to support its deployment of laser enrichment technology in the US.
The development timeline for GLE will be dependent on several factors, including market fundamentals, securing government
funding, support for HALEU availability in the US and GLE’s ability to secure long-term contracts to underpin the deployment
of a commercial facility"
- Forums
- ASX - By Stock
- Cameco Annual Report
SLX
silex systems limited
Add to My Watchlist
2.25%
!
$4.34

The Cameco annual report has been published - the link...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.34 |
Change
-0.100(2.25%) |
Mkt cap ! $1.033B |
Open | High | Low | Value | Volume |
$4.54 | $4.61 | $4.32 | $3.963M | 895.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16533 | $4.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 3059 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1162 | 4.310 |
1 | 338 | 4.260 |
1 | 1185 | 4.210 |
2 | 22090 | 4.200 |
1 | 1130 | 4.180 |
Price($) | Vol. | No. |
---|---|---|
4.410 | 28344 | 1 |
4.520 | 571 | 1 |
4.560 | 800 | 1 |
4.570 | 11982 | 1 |
4.580 | 25000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
SLX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online